Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Subcutaneous MarzAA in Hemophilia
NCT04072237Phase 1Completed
- Sponsor
- Gyre Therapeutics, Inc.
- Start
- Sep 2019
- Primary completion
- Apr 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of marzeptacog alfa (activated) in hemophilia A and hemophilia B (HB), sponsored by Gyre Therapeutics, Inc. Primary endpoints: Area Under the Curve (AUC0-∞ and AUC0-last) up to 8 weeks and Dose-Normalized AUC (AUCT1-T2/Dose) up to 8 weeks. Started Sep 2019; status: completed.
02
Drugs
marzeptacog alfa (activated)
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on NCT04072237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04072237.